Ovid Therapeutics (OVID) Times Interest Earned (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Times Interest Earned came in at -$7.76 in Q1 2026, down 52.65% YoY from -$16.39 in Q1 2025, and down 987.81% on a QoQ basis from -$0.71 in Q3 2025.
Ovid Therapeutics (OVID) Times Interest Earned (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Times Interest Earned data on file, last reported at -$7.76 in Q1 2026.
- Quarterly Times Interest Earned fell 52.65% year-over-year to -$7.76 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.75 (up 10.12% YoY) and the FY2025 annual result came in at -$0.47, up 32.64% from the prior year.
- Times Interest Earned fell to -$7.76 in Q1 2026, from -$0.71 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.12 in Q4 2024 to a low of -$195.84 in Q4 2022.
- A 5-year average of -$15.79 and a median of -$4.8 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned plunged 1675.96% — and 2023, when it soared 98.22%.
- Tracing OVID's Times Interest Earned over 5 years: stood at -$195.84 in 2022, then surged by 98.22% to -$3.49 in 2023, then soared by 96.57% to -$0.12 in 2024, then sank by 495.22% to -$0.71 in 2025, then tumbled by 987.81% to -$7.76 in 2026.
- The last three Times Interest Earned figures came in at -$7.76 (Q1 2026), -$0.71 (Q3 2025), and -$2.05 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -7.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.76 |
| Sep 30, 2025 | -0.71 |
| Jun 30, 2025 | -2.05 |
| Mar 31, 2025 | -5.08 |
| Dec 31, 2024 | -0.12 |
| Sep 30, 2024 | -5.71 |
| Jun 30, 2024 | -1.00 |
| Mar 31, 2024 | -4.52 |
| Dec 31, 2023 | -3.49 |
| Sep 30, 2023 | -0.54 |
| Jun 30, 2023 | -2.42 |
| Mar 31, 2023 | -6.43 |
| Dec 31, 2022 | -195.84 |
| Sep 30, 2022 | -5.53 |
| Jun 30, 2022 | -6.18 |
| Mar 31, 2022 | -5.28 |
| Dec 31, 2021 | -11.03 |
| Sep 30, 2021 | -3.88 |
| Jun 30, 2021 | -2.52 |
| Mar 31, 2021 | 27.36 |